At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Atezolizumab 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Atezolizumab and Daratumumab for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 100 participants across 47 sites in 5 countries.
Detailed Summary
The purpose of the study is to compare the overall response rate (ORR) in non-small cell lung cancer (NSCLC) participants treated with daratumumab in combination with atezolizumab versus atezolizumab alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesFrance, Hungary, Poland, Spain, United States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedJan 2017
Primary CompletionMay 2018
Study CompletionSep 2019
TodayJul 2026
First PostedJan 18, 2017
Enrollment StartDec 23, 2016
Primary CompletionMay 17, 2018
Study CompletionSep 26, 2019
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 9.5 years ago
Interventions
Atezolizumabdrug
Participants will receive atezolizumab 1200 mg intravenously.
Daratumumabdrug
Participants will receive daratumumab 16 mg/kg intravenously.